ALS Association – Lawrence and Isabel Barnett Drug Development Program
There is an urgent need for new and improved therapies for ALS, as there is still no cure. The
Lawrence and Isabel Barnett Drug Development Program seeks to accelerate the availability of
new, effective ALS treatments by supporting the preclinical assessment of novel therapies or
repositioned treatment approaches in preparation for clinical testing. These 2-year awards with
a maximum budget of $500,000 are open to both industry and academic investigators.
Applicants should have a development candidate in hand as this funding opportunity aims to
support programs that have a high probability of entering the clinic within 3 years.
Successful applications will include strong and compelling data supporting the biological
rationale for the proposed treatment and a clear plan for moving it through the essential stages
of development, including essential “go/no-go” decision milestones. Applications should
thoroughly describe what is known about pharmacokinetic and pharmacodynamic (PK/PD)
relationships, including plans to address any gaps in this understanding. Studies can be
performed by a contract research organization in collaboration with the principal investigator